Compare Microsoft (MSFT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs TransMedics Group Inc — how do they compare? Microsoft trades at $491.55 (market cap $3.74T), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Microsoft is far larger — about 1206.5× TransMedics Group Inc's market cap, and Microsoft pays a 0.72% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MSFT | TMDX | |
|---|---|---|
Market Cap | $3.74T | $3.10B |
Volume | 36,654,621 | — |
Sector | Technology | Technology |
52-Week High | $542.07 | $150.42 |
52-Week Low | $352.83 | $61.99 |
Enterprise Value | $3.72T | $3.49B |
Dividend Yield | 0.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $493.21, down 2.54% in the last session, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.74 surpassing the $4.24 estimate. Revenue grew to $281.72 billion in 2025, supported by a net income margin of 40.31% and robust cash flow from operations of $136.16 billion. Recent news highlights AI leadership and Azure momentum, though capital expenditure concerns persist.
Outlook remains positive with an 80.49% analyst buy rating and a $555 consensus price target, implying over 12% upside. Risks include competitive pressures in AI, high valuation multiples like a P/E of 28.07, and macroeconomic volatility. The stock's fundamentals and institutional support suggest long-term growth potential, but investors should monitor execution on AI investments and spending trends.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
